CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach. (Funded by the Beijing Municipal Science and Technology Commission and others; ClinicalTrials.gov number, NCT03164135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subsequent experiments showed that p53 inactivation can be controlled or avoided through protocol optimization 47,107 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [107]
Citations
Cites
1 retracted
CCR5-∆32 is deleterious in the homozygous state in humans
Wei, X., & Nielsen, R. (2019) · Nature Medicine · doi:10.1038/s41591-019-0459-6 · Cited by 75
RetractedIdentification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
Self-citationSamson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802905 · Cited by 1,837
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805817 · Cited by 1,007
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y.-L., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1410 · Cited by 999
Self-citationCRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Cited by
Items 101–200 of 468
Al-Ouqaili, M. T. S., Ahmad, A., Jwair, N. A., & Al-Marzooq, F. I. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1588446 · Cited by 55
An overview of development in gene therapeutics in China
Wang, D., Wang, K., & Cai, Y. (2020) · Gene Therapy · doi:10.1038/s41434-020-0163-7 · Cited by 50
“Though no evidence of therapeutic benefits for HIV, the study showed first in human evidence that CRISPR was safe at least during the 19 months follow-up, which may encourage other ex vivo gene therapy using CRISPRedited HSPCs such as β-thalassemia and sickle cell diseases [36].”
BackgroundHe, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00283-8 · Cited by 46
Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer
Yan, J., Kang, D. D., Turnbull, G., & Dong, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114042 · Cited by 46
Universal toxin-based selection for precise genome engineering in human cells
Li, S., Akrap, N., Cerboni, S., Porritt, M. J., Wimberger, S., Lundin, A., Möller, C., Firth, M. A., Gordon, E., Lazovic, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20810-z · Cited by 47
Paving the way towards precise and safe CRISPR genome editing
Śledziński, P., Dabrowska, M., Nowaczyk, M., & Olejniczak, M. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107737 · Cited by 45
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 48
“Both in vitro transcribed and chemically synthesized gRNAs are being evaluated in ongoing clinical trials.(5,103)”
Advances of Nanoparticles for Leukemia Treatment
Shen, J., Lü, Z., Wang, J., Zhang, T., Yang, H. J., Li, Y., Liu, G., & Zhang, X. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01040 · Cited by 43
Self-citationCD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy
Kim, M. Y., Cooper, M. L., Jacobs, M. T., Ritchey, J., Hollaway, J., Fehniger, T. A., & DiPersio, J. F. (2021) · JCI Insight · doi:10.1172/jci.insight.149819 · Cited by 41
“HSCs has only recently entered human clinical trials (24, 25), and we still await the long-term effects of”
RNA-based therapeutics to treat human fungal infections
Bruch, A., Kelani, A. A., & Blango, M. G. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2021.09.007 · Cited by 39
A short overview of CRISPR-Cas technology and its application in viral disease control
Ghorbani, A., Hadifar, S., Salari, R., Izadpanah, K., Burmistrz, M., Afsharifar, A., Eskandari, M. H., Niazi, A., Denes, C. E., & Neely, G. G. (2021) · Transgenic Research · doi:10.1007/s11248-021-00247-w · Cited by 36
“In addition, the application of SpCas9 and U-modified tracrRNA in the ribonucleoprotein complex (RNP) delivery format was found to improve indel formation in LTRs and could reduce CCR5 surface receptor expression in primary CD4 T-cells (Scott et al. 2019; Xu et al. 2019)Together, these results highlight the”
BackgroundMethodEfficient mRNA delivery to resting T cells to reverse HIV latency
Cevaal, P. M., Kan, S., Fisher, B. M., Moso, M. A., Tan, A., Liu, H., Ali, A., Tanaka, K., Shepherd, R. A., Kim, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60001-2 · Cited by 38
Rust, B. J., Kiem, H., & Uldrick, T. S. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30142-3 · Cited by 39
Werder, R. B., Kaserman, J. E., Packer, M. S., Lindstrom-Vautrin, J., Villacorta-Martín, C., Young, L. E., Aratyn-Schaus, Y., Gregoire, F. M., & Wilson, A. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.021 · Cited by 39
Li, S., Holguin, L., & Burnett, J. C. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.012 · Cited by 45
Current advances of CRISPR-Cas technology in cell therapy
Qiu, H.-Y., Ji, R.-J., & Zhang, Y. (2022) · Cell Insight · doi:10.1016/j.cellin.2022.100067 · Cited by 41
“To further test the concept, CCR5 ablated HSPCs was transplanted into a 27-year-old man with HIV-positive and acute lymphoblastic leukemia (NCT03164135; Xu et al., 2019).”
MethodSelf-citationThe Future of Skull Base Surgery: A View Through Tinted Glasses
Sekhar, L. N., Juric‐Sekhar, G., Zeeshan, Q., Patel, A. P., McGrath, L. B., Pridgeon, J. S., Kalavakonda, N., & Hannaford, B. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.06.172 · Cited by 37
“WORLD NEUROSURGERY 142: 29-42, OC already shown promise in editing hematopoietic lineage cells in stem cell transplantation and conferring human immunodeficiency virus resistance.(16) One application to skull base tumors would be to correct pathologic point mutations in genes underlying CNS tumor syndromes, such as th…”
BackgroundRaigani, M., Eftekhari, Z., Adeli, A., & Kazemi‐Lomedasht, F. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102666 · Cited by 46
“178 Following transplantation, the patient’s ALL reached complete remission with full donor chimerism, and the edited donor cells lacking CCR5 were detectable for over 19 months without any adverse effects related to the gene editing.”
The Daunting Economics of Therapeutic Genome Editing
Wilson, R. C., & Carroll, D. (2019) · The CRISPR Journal · doi:10.1089/crispr.2019.0052 · Cited by 33
“Reported ex vivo genome-editing trials that involved making a CCR5 knockout in patient cells (either T cells 1 or their hematopoietic progenitors 3 ) to combat HIV showed that these procedures could be done safely.”
Harnessing the evolving CRISPR/Cas9 for precision oncology
Li, T., Li, S., Kang, Y., Zhou, J., & Yi, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05570-4 · Cited by 40
“The first successful attempt to employ CRISPR/Cas9 in humans involved the reinfusion of CCR5 hematopoietic stem and progenitor cells (HSPCs) into HIV patients in 2019, yielding modestly promising outcomes [37].”
BackgroundLayer-by-Layer technique as a versatile tool for gene delivery applications
Linnik, D., Tarakanchikova, Y. V., Zyuzin, M. V., Lepik, K. V., Aerts, J. L., Sukhorukov, G. B., & Timin, A. S. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1879790 · Cited by 35
“Importantly, HSCs are small-sized quiescent cells with no active phagocytosis function, representing a hard-to-transfect cell type.”
MethodInfluentialCAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Testa, U., Sica, S., Pelosi, E., Castelli, G., & Leone, G. G. M. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.010 · Cited by 38
Genomics in medicine: A new era in medicine
Pattan, V., Kashyap, R., Bansal, V., Candula, N., Koritala, T., & Surani, S. (2021) · World Journal of Methodology · doi:10.5662/wjm.v11.i5.231 · Cited by 33
Haemopoietic cell transplantation in patients living with HIV
Ambinder, R. F., Capoferri, A. A., & Durand, C. M. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30117-x · Cited by 32
The chemokine receptor CCR5: multi-faceted hook for HIV-1
Faivre, N., Vérollet, C., & Dumas, F. (2024) · Retrovirology · doi:10.1186/s12977-024-00634-1 · Cited by 34
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
“…these studies under-score the importance of monitoring residual genome editor content during the manufacturing process, which has not been taken into consideration in early Cas9-based clinical trials, 113,114 potentially resulting in genome editor carry-over to the recipients upon infusion.”
Cornu, T. I., Mussolino, C., Müller, M. C., Wehr, C., Kern, W. V., & Cathomen, T. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.159 · Cited by 36
“104 In order of such an approach to be successful, CCR5 editing in CD34 cells must be both highly efficient and highly specific, which can be achieved by TALEN and CRISPR-Cas nucleases.”
CRISPR-based therapeutic genome editing for inherited blood disorders
Levesque, S., & Bauer, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01236-y · Cited by 39
“This new paradigm in molecular medicine could potentially be extended to other blood and immune disorders, including but not limited to inherited bone marrow failure syndromes 21 , immunodeficiencies 22–25 , lysosomal storage diseases 26 and even acquired diseases such as HIV infection 27,28 .”
A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
Chen, X., Guo, R., Zhao, C., Xu, J., Song, H., Yu, H., Pilarsky, C. P., Nainu, F., Li, J., Zhou, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.939090 · Cited by 34
“For example, through gene editing of CCR5 in CD4 T cells from persons who have been infected with HIV helps to combat HIV infection (Hsu et al., 2014; Tebas et al., 2014; Xu et al., 2019).”
BackgroundSelf-citationApproaches to Enhance Precise CRISPR/Cas9-Mediated Genome Editing
Denes, C. E., Cole, A. J., Aksoy, Y. A., Li, G., Neely, G. G., & Hesselson, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168571 · Cited by 32
“CRISPR/Cas9-edited donor cells persisted for at least 19 months after transplantation, without adverse events [8].”
BackgroundEngineering guide RNA to reduce the off-target effects of CRISPR
Wu, J., & Yin, H. (2019) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.003 · Cited by 29
Xu, M. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00410-6 · Cited by 29
Applications of cell therapy in the treatment of virus-associated cancers
Toner, K., McCann, C. D., & Bollard, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00930-x · Cited by 31
“However, this approach is currently limited by the low efficiency of CCR5 disruption using current technologies 157 .”
Wu, L., Jiang, S., Shi, M., Yuan, T., Li, Y., Huang, P., Li, Y., Zuo, E., Zhou, C., & Sun, Y. (2024) · Genome biology · doi:10.1186/s13059-024-03434-0 · Cited by 31
“Both ABE and Cas9 systems have been widely applied in the treatment of various diseases [45, 55–57].”
BackgroundCRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedside
Humbert, O., Samuelson, C., & Kiem, H. (2020) · British Journal of Haematology · doi:10.1111/bjh.16807 · Cited by 27
“Results from trial NCT03164135 were recently reported for one HIV patient suffering from acute lymphoblastic leukaemia who received donor stem cells from an HLA-compatible donor.(69) CCR5edited HSPCs stably engrafted, as represented by 5 to 8% editing frequencies detected in bone marrow and blood at 19 months post-tra…”
BackgroundFirst Trial of CRISPR-Edited T cells in Lung Cancer
Lacey, S. F., & Fraietta, J. A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.06.001 · Cited by 27
Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing
Xu, Y., Liu, R., & Dai, Z. (2020) · Nanoscale · doi:10.1039/d0nr05452f · Cited by 29
High concentration of Cas12a effector tolerates more mismatches on ssDNA
Li, H., Cui, X., Sun, L., Deng, X., Liu, S., Zou, X., Li, B., Wang, C., Wang, Y., Liu, Y., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202001475r · Cited by 30
Self-citationCRISPR/Cas based gene editing: marking a new era in medical science
Prasad, K. M., George, A., Ravi, N. S., & Mohankumar, K. M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06479-7 · Cited by 35
Immunity and Viral Infections: Modulating Antiviral Response via CRISPR–Cas Systems
Brezgin, S. A., Kostyusheva, A. P., Олеговна, Б. Е., Volchkova, E. V., Gegechkori, V., Gordeychuk, I. V., Glebe, D., Kostyushev, D. S., & Chulanov, V. (2021) · Viruses · doi:10.3390/v13071373 · Cited by 31
Updates on CRISPR-based gene editing in HIV-1/AIDS therapy
Zhang, Z., Hou, W., & Chen, S. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.01.017 · Cited by 35
“The AML was alleviated; however, the replication of HIV-1 was only suppressed, and AIDS cure was not achieved due to the low gene editing efficiency (Xu et al., 2019).”
BackgroundMethodInfluentialGenome editing of CCR5 by AsCpf1 renders CD4+T cells resistance to HIV-1 infection
Liu, Z., Liang, J. H., Chen, S., Wang, K., Liu, X., Liu, B., Xia, Y., Guo, M., Zhang, X., Sun, G., et al. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00444-w · Cited by 30
Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure
Ding, J., Liu, Y., & Lai, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.688747 · Cited by 31
“Furthermore, the CCR5-edited frequencies of CD4+ cells (approximately 2%) and CD8+ cells (approximately 1%) in peripheral blood were far lower than that of other cells, which was not sufficient to achieve the aim of an HIV cure (40).”
BackgroundSelf-citationBasic Principles and Clinical Applications of CRISPR-Based Genome Editing
Lim, J. M., & Kim, S. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.2.105 · Cited by 28
Marei, H. E. S., Khan, M. U. A., & Hasan, A. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00504-2 · Cited by 29
“No adverse effects were observed in this area from studies of human immunodeficiency virus (HIV) and acute lymphoblastic leukemia (ALL) [180].”
BackgroundRomito, M., Juillerat, A., Kok, Y. L., Hildenbeutel, M., Rhiel, M., Andrieux, G., Geiger, J. P., Rudolph, C., Mussolino, C., Duclert, A., et al. (2020) · Biotechnology Journal · doi:10.1002/biot.202000023 · Cited by 30
CRISPR/Cas therapeutic strategies for autosomal dominant disorders
Caruso, S. M., Quinn, P. M. J., da Costa, B. L., & Tsang, S. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158287 · Cited by 29
Protière, C., Arnold, M. P., Fiorentino, M., Fressard, L., Lelièvre, J., Mimi, M., Raffi, F., Mora, M., Meyer, L., Sagaon‐Teyssier, L., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25443 · Cited by 25
Fix, S. M., Jazaeri, A. A., & Hwu, P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1083 · Cited by 26
Gene editing to enhance the efficacy of cancer cell therapies
Murty, T., & Mackall, C. L. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.001 · Cited by 26
Pathways towards human immunodeficiency virus elimination
Dash, P. K., Kevadiya, B. D., Su, H., Banoub, M. G., & Gendelman, H. E. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102667 · Cited by 25
“However, the approaches lacked sensitivity and specificity and as such, led to the use of the CRISPR system [27,116].”
BackgroundNewman, A., Starrs, L. M., & Burgio, G. (2020) · BioEssays · doi:10.1002/bies.202000047 · Cited by 31
Interpreting CRISPR-Cas12a enzyme kinetics through free energy change of nucleic acids
Zhang, J., Guan, X., Moon, J., Zhang, S., Jia, Z., Yang, R., Hou, C., Guo, C., Pei, M., & Liu, C. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1124 · Cited by 27
In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations
Psatha, N., Paschoudi, K., Παπαδοπούλου, Α., & Yannaki, E. (2022) · Genes · doi:10.3390/genes13122222 · Cited by 25
“Remarkably, the transplantation of allogeneic, CRISPR-edited, CCR5-ablated HPSCs into a patient with HIV-1 infection and acute lymphoblastic leukemia resulted in long-term engraftment of genetically modified HSPCs, yet with only 5% CCR5 disruption rates in lymphocytes [52].”
BackgroundKey considerations in formulation development for gene therapy products
Mohammad, R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.013 · Cited by 24
Development and Application of CRISPR-Cas Based Tools
Hu, Y., & Li, W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.834646 · Cited by 26
Quest to use CRISPR against disease gains ground
Ledford, H. K. (2020) · Nature · doi:10.1038/d41586-019-03919-0 · Cited by 24
Mitochondrial Genome Editing to Treat Human Osteoarthritis—A Narrative Review
Zhong, G., Madry, H., & Cucchiarini, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031467 · Cited by 24
Zhou, W., Yang, J., Zhang, Y., Hu, X., & Wang, W. (2022) · MedComm · doi:10.1002/mco2.155 · Cited by 31
Self-citationHeeren, J. J. F. (2022) · BioTech · doi:10.3390/biotech11030025 · Cited by 25
“Another possibility would be the use of gene-edited stem cells, such as HSC, or iPSC-derived HSCs.”
BackgroundInfluentialGene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments
Mbakam, C. H., & Tremblay, J. P. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2249607 · Cited by 24
Advancements in CRISPR screens for the development of cancer immunotherapy strategies
Li, Y.-R., Lyu, Z., Tian, Y., Fang, Y., Zhu, Y., Chen, Y., & Yang, L. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.100733 · Cited by 23
Bai, Y., Nan, Y., Wu, T., Zhu, A., Xie, X., Sun, Y., Deng, Y., Dou, Z., Hu, X., Zhou, R., et al. (2024) · Advanced Science · doi:10.1002/advs.202400493 · Cited by 28
Self-citationEditing out HIV: application of gene editing technology to achieve functional cure
Xun, J., Zhang, X., Guo, S., Lu, H., & Chen, J. (2021) · Retrovirology · doi:10.1186/s12977-021-00581-1 · Cited by 24
Rathbone, T., Ates, I., Fernando, L. P., Addlestone, E., Lee, C. M., Richards, V. P., & Cottle, R. N. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0134 · Cited by 24
Biosynthetic Nanobubble-Mediated CRISPR/Cas9 Gene Editing of Cdh2 Inhibits Breast Cancer Metastasis
Gao, R., Luo, Q., Li, Y., Song, L., Cai, J., Xiong, Y., Yan, F., & Liu, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071382 · Cited by 24
CRISPR/CAS9: A promising approach for the research and treatment of cardiovascular diseases
Dong, M., Liu, J., Liu, C., Wang, H., Sun, W. Y., & Liu, B. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106480 · Cited by 23
Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Schwarze, L. I., Głów, D., Sonntag, T., Uhde, A., & Fehse, B. (2021) · Gene Therapy · doi:10.1038/s41434-021-00271-9 · Cited by 24
Gene knockout in cellular immunotherapy: Application and limitations
Zhang, X., Jin, X. K., Sun, R., Zhang, M., Lu, W., & Zhao, M. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215736 · Cited by 25
A Nobel Prize for genetic scissors
(2020) · Nature Materials · doi:10.1038/s41563-020-00895-z · Cited by 22
Genome editing of immune cells using CRISPR/Cas9
Kim, S., Hupperetz, C., Kim, C. H., & Kim, C. H. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.245 · Cited by 26
Karuppusamy, K. V., Demosthenes, J. P., Venkatesan, V., Christopher, A. C., Babu, P., Azhagiri, M. K. K., Jacob, A., Ramalingam, V. V., Rangaraj, S., Mohankumar, K. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.792684 · Cited by 24
“Although both strategies were proved safe in clinical studies, they failed to provide functional cure (14).”
BackgroundMaslennikova, A., & Mazurov, D. V. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.880030 · Cited by 27
Advancements in Cell-Based Therapies for HIV Cure
Matsui, Y., & Miura, Y. (2023) · Cells · doi:10.3390/cells13010064 · Cited by 22
“Alternatively, the infusion of hematopoietic stem and progenitor cells or CD4 + T cells edited for the CCR5 gene into HIV-1-infected patients [75–77] can generate CD4 + T cells resistant to HIV-1.”
BackgroundGenome-edited adult stem cells: Next-generation advanced therapy medicinal products
Benabdellah, K., Sánchez-Hernández, S., Aguilar-González, A., Maldonado‐Pérez, N., Gutiérrez-Guerrero, A., Cortijo-Gutierréz, M., Ramos-Hernández, I., Tristán‐Manzano, M., Galindo‐Moreno, P., Herrera, C., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0338 · Cited by 23
“The SCD patient also underwent significant F IGURE 4 Diagram showing the principal steps in a clinical trial using autologous as compared to allogenic HSPCs. HPSCs were harvested from patients and healthy donors and cultivated in vitro.”
BackgroundInfluentialSheykhhasan, M., Foroutan, A., Manoochehri, H., Khoei, S. G., Poondla, N., & Saidijam, M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119451 · Cited by 23
CRISPR Technology and Its Emerging Applications
Zhang, X. E., Ma, D., & Liu, F. (2025) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzaf034 · Cited by 23
“The patient achieved complete remission of AML four weeks post-transplantation [153].”
Human induced-T-to-natural killer cells have potent anti-tumour activities
Jiang, Z., Qin, L., Tang, Y., Liao, R. J., Shi, J., He, B., Li, S., Zheng, D., Cui, Y., Wu, Q., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00358-4 · Cited by 20
“A computational tool predicted 669 potential off-target sites with 3 mismatches and 1 bulge size [81, 82].”
MethodXia, K., Wang, F., Tan, Z., Zhang, S., Lai, X., Ou, W., Yang, C., Chen, H., Peng, H. Y., Luo, P., et al. (2023) · Advanced Science · doi:10.1002/advs.202300993 · Cited by 23
Self-citationKhamaikawin, W., Saisawang, C., Tassaneetrithep, B., Bhukhai, K., Phanthong, P., Borwornpinyo, S., Phuphuakrat, A., Pasomsub, E., Chaisavaneeyakorn, S., Anurathapan, U., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61626-x · Cited by 20
“To generate the knockout CCR5, a pair of sgRNA were selected to target human CCR5 gene to produce efficient cleavage activity and eliminate off-target effects 11,14 .”
BackgroundMethodInfluentialAdvancements in p53-Based Anti-Tumor Gene Therapy Research
Peng, Y., Bai, J., Wang, L., Su, Z., & Cheng, X. (2024) · Molecules · doi:10.3390/molecules29225315 · Cited by 25
Self-citationAcute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers
Forghieri, F., Nasillo, V., Bettelli, F., Pioli, V., Giusti, D., Gilioli, A., Mussini, C., Tagliafico, E., Trenti, T., Cossarizza, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031081 · Cited by 20
“recently described, in a HIV-infected patient with acute lymphoblastic leukemia, the proof of principle that transplantation and long-term engraftment of CRISP-edited CCR5-ablated allogeneic HSC can be obtained, without significant adverse events [98].”
BackgroundDudek, A. M., Feist, W. N., Sasu, E. J., Luna, S. E., Ben-Efraim, K., Bak, R. O., Cepika, A.-M., & Porteus, M. H. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.03.002 · Cited by 19
Li, M., Xu, Y., Li, K., Chao Hui, Z. H. O. U., Fan, X.-X., Wang, H., Shi, P., Li, R.-T., Wang, Z.-X., Cao, T.-S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63323-3 · Cited by 22
“Additionally,emergingtechnologiessuchasCRISPR-based genome editing can also be applied to DENV treatment as well, which has been used to treat various diseases 88 – 90 and to fi ght virus infection 91,92 .”
Eliminating the HIV tissue reservoir: current strategies and challenges
Li, K., & Zhang, Q. (2023) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2023.2298450 · Cited by 24
“This study provides an important reference and guidance for further improving the use of gene editing technology to treat and cure AIDS [87].”
BackgroundNext-generation CRISPR technology for genome, epigenome and mitochondrial editing
Lau, C., Liang, Q., & Zhu, H. (2024) · Transgenic Research · doi:10.1007/s11248-024-00404-x · Cited by 21
“Another recent study also has demonstrated successful transplantation and long-term engraftment of CRISPR-edited CCR5-ablated hematopoietic stem and progenitor cells into a patient with HIV-1 infection and acute lymphoblastic leukemia (Xu et al. 2019).”
Controlling CRISPR with small molecule regulation for somatic cell genome editing
Khajanchi, N., & Saha, K. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.014 · Cited by 22
Targeting CCR5: A central approach to HIV treatment and cure strategies
Yükselten, Y., Wishah, H., Li, J. A., & Sutton, R. E. (2024) · Virology · doi:10.1016/j.virol.2024.110375 · Cited by 19
Gene Editing in Pluripotent Stem Cells and Their Derived Organoids
Zhou, H., Wang, Y., Liu, L., Li, Y., & Zheng, Y. (2021) · Stem Cells International · doi:10.1155/2021/8130828 · Cited by 22
“Furthermore, transplantation of gene-edited HSCs and progenitor cells (HSPCs) to a leukemia patient with a simultaneous HIV-1 infection was proven to be safe [5].”
BackgroundSelf-citationClinical trials and promising preclinical applications of CRISPR/Cas gene editing
Çerçi, B., Uzay, İ. A., Kara, M. K., & Dinçer, P. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121204 · Cited by 22
HIV reservoir: antiviral immune responses and immune interventions for curing HIV infection
Li, S., Moog, C., Zhang, T., & Su, B. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002479 · Cited by 19
“Although we achieved successful transplantation and long-term engraftment of CRISPR-edited hematopoietic stem and progenitor cells, the percentage of CCR5 disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach.([85]) Further studies on CCR5-defective cells…”
BackgroundSelf-citationKitawi, R. C., Ledger, S., Kelleher, A. D., & Ahlenstiel, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052771 · Cited by 24
Genome-wide detection and analysis of CRISPR-Cas off-targets
Rodríguez, T., Dadafarin, S., Pratt, H., Liu, P., Amrani, N., & Zhu, L. J. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.012 · Cited by 19
Rapid, precise quantification of large DNA excisions and inversions by ddPCR
Watry, H. L., Feliciano, C. M., Gjoni, K., Takahashi, G., Miyaoka, Y., Conklin, B. R., & Judge, L. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-71742-z · Cited by 18
In vivo evaluation of guide-free Cas9-induced safety risks in a pig model
Ge, W., Gou, S., Zhao, X., Jin, Q., Zhuang, Z., Zhao, Y., Liang, Y., Ouyang, Z., Liu, X., Chen, F., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01905-1 · Cited by 19
“…CRISPR/Cas9-mediated gene therapy has been applied in clinical trials for treating various genetic diseases or refractory conditions, 6 such as sickle cell disease, 7 β -thalassemia, 7,8 transthyretin amyloidosis, 9 retinal degeneration, 10 acquired immunode fi ciency syndrome, 11 and cancers.”
BackgroundMethodSelf-citationBairqdar, A., Karitskaya, P. E., & Stepanov, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413321 · Cited by 20
“Despite the positive in vitro results obtained by the group [79], the findings of the clinical trial were not published.”
In silico Method in CRISPR/Cas System: An Expedite and Powerful Booster
Zhang, Y., Zhao, G., Ahmed, F. Y. H., Yi, T., Hu, S., Cai, T., & Liao, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584404 · Cited by 20
“Up to now, CRISPR/Cas system has been extensively applied in fundamental studies (9) as well as clinical practices across multiple diseases (10, 11).”
BackgroundSelf-citationHawsawi, Y. M., Shams, A. M., Theyab, A., Siddiqui, J., Barnawee, M., Abdali, W. A., Marghalani, N. A., Alshelali, N. H., Al-Sayed, R., Alzahrani, O. R., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.869889 · Cited by 20
Implications of hematopoietic stem cells heterogeneity for gene therapies
Epah, J., & Schäfer, R. (2021) · Gene Therapy · doi:10.1038/s41434-021-00229-x · Cited by 18
Claiborne, D. T., Detwiler, Z., Docken, S. S., Borland, T. D., Cromer, D., Simkhovich, A., Ophinni, Y., Okawa, K., Bateson, T., Chen, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55873-3 · Cited by 16
Metadata
- Authors
- Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., Zhao, L., Hu, L., Ning, H., Zhang, Y., Deng, K., Liu, L., Lu, X., Zhang, T., Xu, J., Li, C., Wu, H., Deng, H., & Chen, H.
- Affiliations
- Peking University (CN)
- Capital Medical University (CN)
- Sun Yat-sen University (CN)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-26
- Volume
- 381
- Issue
- 13
- Pages
- 1240-1247
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2972390440
- Cited by
- 454
- References
- 27
- Citations by year
- 2026: 34 · 2025: 52 · 2024: 57 · 2023: 45 · 2022: 77 · 2021: 87 · 2020: 89 · 2019: 13
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Key Research and Development Program of China (2017YFA0103000)
- Beijing Municipal Science and Technology Commission (D171100000517004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR gene editing, hematopoietic stem cells, HIV, acute lymphoblastic leukemia, gene therapy
- MeSH terms
- Gene Editing, Adult, Blood Cell Count, Hematopoietic Stem Cells, Humans, Male, HIV-1, HIV Infections, Hematopoietic Stem Cell Transplantation, CD4 Lymphocyte Count, Viral Load, Receptors, CCR5, Anti-Retroviral Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.